نتائج البحث - Ilene Galinsky

تنقيح النتائج
  1. 1
    Small-Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells

    Small-Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells حسب Helena Mistry, Grace Hsieh, Sara J. Buhrlage, Min Huang, Eunmi Park, Gregory D. Cuny, Ilene Galinsky, Richard M. Stone, Nathanael S. Gray, Alan D. D’Andrea, Kalindi Parmar

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells

    KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells حسب Julia Etchin, Alla Berezovskaya, Amy Saur Conway, Ilene Galinsky, Richard M. Stone, Erkan Baloglu, William Senapedis, Yosef Landesman, Michael Kauffman, Sharon Shacham, Jean Wang, A. Thomas Look

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia

    Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia حسب Patrick Bhola, Brenton G. Mar, R. Coleman Lindsley, Jeremy Ryan, Leah J. Hogdal, Thanh Trang Vo, Daniel J. DeAngelo, Ilene Galinsky, Benjamin L. Ebert, Anthony Letai

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

    Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells حسب Ellen Weisberg, Renee D. Wright, Douglas W. McMillin, Constantine S. Mitsiades, Arghya Ray, Rosemary Barrett, Sophia Adamia, Richard M. Stone, Ilene Galinsky, Andrew L. Kung, James D. Griffin

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema

    Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema حسب Matthew Torre, Isaac H. Solomon, Claire L. Sutherland, Sarah Nikiforow, Daniel J. DeAngelo, Richard M. Stone, Henrikas Vaitkevicius, Ilene Galinsky, Robert F. Padera, Nikolaus S. Trede, Sandro Santagata

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Smac mimetics: implications for enhancement of targeted therapies in leukemia

    Smac mimetics: implications for enhancement of targeted therapies in leukemia حسب Ellen Weisberg, Arghya Ray, Rosemary Barrett, Erik A. Nelson, Amanda L. Christie, Dale Porter, Christopher Straub, Leigh Zawel, John Daley, Suzan Lazo-Kallanian, Richard Stone, Ilene Galinsky, David A. Frank, Andrew L. Kung, James D. Griffin

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL– and mutant FLT3-expressing cells

    Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL– and mutant FLT3-expressing cells حسب Ellen Weisberg, Lolita Banerji, Renee D. Wright, Rosemary Barrett, Arghya Ray, Daisy Moreno, Laurence Catley, Jingrui Jiang, Elizabeth Hall–Meyers, Sauveur-Michel Maira, Richard M. Stone, Ilene Galinsky, Edward Fox, Andrew L. Kung, James D. Griffin

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells

    Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells حسب Haymanti Bhanot, Mamatha M. Reddy, Atsushi Nonami, Ellen Weisberg, Dennis Bonal, Paul Kirschmeier, Sabrina Salgia, Klaus Podar, Ilene Galinsky, Tirumala Kumar Chowdary, Donna Neuberg, Giovanni Tonon, Richard M. Stone, John M. Asara, James D. Griffin, Martin Sattler

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

    Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 حسب Richard M. Stone, Daniel J. DeAngelo, Virginia M. Klimek, Ilene Galinsky, Eli Estey, Stephen D. Nimer, Wilson Grandin, David Lebwohl, Yanfeng Wang, Pamela Cohen, Edward A. Fox, Donna Neuberg, Jennifer Clark, D. Gary Gilliland, James D. Griffin

    منشور في 2004
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors

    Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors حسب Mark J. Levis, Patrick A. Brown, B. Douglas Smith, Adam Stine, Rosalyn Pham, Richard M. Stone, Daniel A. DeAngelo, Ilene Galinsky, Frank Giles, Elihu H. Estey, Hagop M. Kantarjian, Pamela Cohen, Yanfeng Wang, Johannes Roesel, Judith E. Karp, Donald Small

    منشور في 2006
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors

    Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK i... حسب Ellen Weisberg, Qingsong Liu, Erik A. Nelson, Andrew L. Kung, Amanda L. Christie, Rod T. Bronson, Martin Sattler, Takaomi Sanda, Zheng Zhao, Won Hur, C Mitsiades, R Smith, J F Daley, Richard M. Stone, Ilene Galinsky, J D Griffin, Nathanael S. Gray

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia

    SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia حسب Alexandre Puissant, Nina Fenouille, Gabriela Alexe, Yana Pikman, Christopher F. Bassil, Swapnil Mehta, Jinyan Du, Julhash U. Kazi, Frédéric Luciano, Lars Rönnstrand, Andrew L. Kung, Jon C. Aster, Ilene Galinsky, Richard M. Stone, Daniel J. DeAngelo, Michael T. Hemann, Kimberly Stegmaier

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells

    MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells حسب Dina Stroopinsky, Jacalyn Rosenblatt, Keisuke Ito, Heidi Mills, Li Yin, Hasan Rajabi, Baldev Vasir, Turner Kufe, Katarina Luptakova, Jon Arnason, Caterina Nardella, James D. Levine, Robin Joyce, Ilene Galinsky, Yoram Reiter, Richard M. Stone, Pier Paolo Pandolfi, Donald Küfe, David Avigan

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia

    MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia حسب Yana Pikman, Benjamin H. Lee, Thomas Mercher, Elizabeth McDowell, Benjamin L. Ebert, Maricel Gozo, Adam Cuker, Gerlinde Wernig, Sandra Moore, Ilene Galinsky, Daniel J. DeAngelo, Jennifer Clark, Stephanie J. Lee, Todd R. Golub, Martha Wadleigh, D. Gary Gilliland, Ross L. Levine

    منشور في 2006
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401

    Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401 حسب Arti Hurria, Constance Cirrincione, Hyman B. Muss, Alice B. Kornblith, William T. Barry, Andrew Artz, Linda E. Schmieder, Rafat Ansari, William P. Tew, Douglas Weckstein, Jeffrey Kirshner, Kayo Togawa, Kurt Hansen, Vani Katheria, Richard M. Stone, Ilene Galinsky, John Postiglione, Harvey Jay Cohen

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax

    Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax حسب Joan Montero, Jason Stephansky, Tianyu Cai, Gabriel K. Griffin, Lucía Cabal‐Hierro, Katsuhiro Togami, Leah J. Hogdal, Ilene Galinsky, Elizabeth A. Morgan, Jon C. Aster, Matthew S. Davids, Nicole R. LeBoeuf, Richard M. Stone, Marina Konopleva, Naveen Pemmaraju, Anthony Letai, Andrew A. Lane

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia

    Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia حسب Eyal C. Attar, Daniel J. DeAngelo, Jeffrey G. Supko, Ferdinando D’Amato, David Zahrieh, Andres Sirulnik, Martha Wadleigh, Karen K. Ballen, Steve McAfee, Kenneth B. Miller, James D. Levine, Ilene Galinsky, Elizabeth Trehu, David P. Schenkein, Donna Neuberg, Richard M. Stone, Philip C. Amrein

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

    Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-R... حسب Thomas Fischer, Richard M. Stone, Daniel J. DeAngelo, Ilene Galinsky, Elihu H. Estey, Carlo Lanza, Edward Fox, Gerhard Ehninger, Eric J. Feldman, Gary J. Schiller, Virginia M. Klimek, Stephen D. Nimer, D. Gary Gilliland, Catherine Dutreix, Alice Huntsman-Labed, J. D. Virkus, Francis J. Giles

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML

    Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML حسب Jingrui Jiang, J. Guillermo Paez, Jeffrey C. Lee, Ronghai Bo, Richard M. Stone, Daniel J. DeAngelo, Ilene Galinsky, Brian M. Wolpin, Anna Jonášová, Paula Herman, Edward A. Fox, Titus J. Boggon, Michael J. Eck, Ellen Weisberg, James D. Griffin, D. Gary Gilliland, Matthew Meyerson, William R. Sellers

    منشور في 2004
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

    Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097 حسب Ellen Weisberg, Ensar Halilovic, Vesselina G. Cooke, Atsushi Nonami, Tao Ren, Takaomi Sanda, Irene Simkin, Jing Yuan, Brandon Antonakos, Louise Barys, Moriko Ito, Richard M. Stone, Ilene Galinsky, Kristen Cowens, Erik A. Nelson, Martin Sattler, Sébastien Jeay, Jens Wuerthner, Sean M. McDonough, Marion Wiesmann, James D. Griffin

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: